Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 25:13:1208741.
doi: 10.3389/fonc.2023.1208741. eCollection 2023.

Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma

Katia Mancuso  1   2 , Elena Zamagni  1   2 , Vincenza Solli  1   2 , Liliana Gabrielli  3 , Marta Leone  4 , Lucia Pantani  1 , Serena Rocchi  1   2 , Ilaria Rizzello  1   2 , Paola Tacchetti  1 , Stefano Ghibellini  1   2 , Emanuele Favero  1   2 , Margherita Ursi  1   2 , Marco Talarico  1   2 , Simona Barbato  1   2 , Ajsi Kanapari  2 , Flavia Bigi  1   2 , Michele Puppi  1   2 , Carolina Terragna  1 , Enrica Borsi  1   2 , Marina Martello  1   2 , Andrea Poletti  1   2 , Alessandra Scatà  1 , Giuliana Nepoti  1 , Barbara Ruffini  1 , Tiziana Lazzarotto  3   4 , Michele Cavo  1   2
Affiliations

Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma

Katia Mancuso et al. Front Oncol. .

Abstract

Long-term kinetics of antibody (Ab) and cell-mediated immune (CMI) response to full anti-SARS-CoV-2 vaccine schedule and booster doses in Multiple Myeloma (MM) patients remain unclear. We prospectively evaluated Ab and CMI response to mRNA vaccines in 103 SARS-CoV-2-naïve MM patients (median age 66, 1 median prior line of therapy) and 63 health-workers. Anti-S-RBD IgG (Elecsys®assay) were measured before vaccination and after 1 (T1), 3 (T3), 6 (T6), 9 (T9) and 12 (T12) months from second dose (D2) and 1 month after the introduction of the booster dose (T1D3). CMI response (IGRA test) was evaluated at T3 and T12. Fully vaccinated MM patients displayed high seropositivity rate (88.2%), but low CMI response (36.2%). At T6 the median serological titer was halved (p=0.0391) in MM patients and 35% reduced (p=0.0026) in controls. D3 (94 patients) increased the seroconversion rate to 99% in MM patients and the median IgG titer in both groups (up to 2500 U/mL), maintained at T12. 47% of MM patients displayed a positive CMI at T12 and double-negativity for humoral and CMI (9.6% at T3) decreased to 1%. Anti-S-RBD IgG level ≥346 U/mL showed 20-times higher probability of positive CMI response (OR 20.6, p<0.0001). Hematological response ≥CR and ongoing lenalidomide maintenance enhanced response to vaccination, hindered by proteasome inhibitors/anti-CD38 monoclonal antibodies. In conclusion, MM elicited excellent humoral, but insufficient cellular responses to anti-SARS-CoV-2 mRNA vaccines. Third dose improved immunogenicity renewal, even when undetectable after D2. Hematological response and ongoing treatment at vaccination were the main predictive factors of vaccine immunogenicity, emphasizing the role of vaccine response assessment to identify patients requiring salvage approaches.

Keywords: SARS-CoV-2; cellular response; humoral response; immunogenicity; mRNA-vaccines; multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

KM has received Honoraria from Celgene, Takeda, Amgen, Sanofi and Janssen. EZ has received honoraria from Janssen, Bristol-Myers Squibb, Amgen, Takeda. LP has received Honoraria from Janssen and Amgen. SR receives Honoraria from Amgen, GlaxoSmithKline and Janssen. IR has received Honoraria from Amgen, GlaxoSmithKline and Sanofi. PT has received Honoraria from Amgen, Bristol-Myers Squibb/Celgene, Janssen, Takeda, AbbVie, Sanofi, GlaxoSmithKline and Oncopeptides. MC has served in a consulting/advisory role for Amgen, AbbVie, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Menarini Stemline, Sanofi, and Karyopharm Therapeutics, and has received honoraria from Amgen, AbbVie, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Menarini Stemline, Sanofi, and Karyopharm Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.

References

    1. Ludwig H, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, et al. . Recommendations for vaccination in multiple myeloma: a consensus of the European myeloma network. Leukemia (2021) 35(1):31–44. doi: 10.1038/s41375-020-01016-0 - DOI - PMC - PubMed
    1. Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. . Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol (2020) 7(10):e737–45. doi: 10.1016/s2352-3026(20)30251-9 - DOI - PMC - PubMed
    1. Martinez-Lopez J, Hernandez-Ibarburu G, Alonso R, Alonso R, Sanchez-Pina JM, Zamanillo I, et al. . Impact of COVID-19 in patients with multiple myeloma based on a global data network. Blood Cancer J (2021) 11(12):198. doi: 10.1038/s41408-021-00588-z - DOI - PMC - PubMed
    1. Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, et al. . Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the international myeloma society data set. Blood (2020) 136(26):3033–40. doi: 10.1182/blood.2020008150 - DOI - PMC - PubMed
    1. IInternational Myeloma Society Recommendations for anti-COVID-19 vaccination in patients with multiple myeloma (MM) and related conditions, AL amyloidosis and other monoclonal gammopathies of clinical significance. (2021). Available at: https://myeloma.wpengine.com/wp-content/uploads/2021/03/PM-COVID-vaccina....